Radionuclide therapy effective in high-grade neuroendocrine neoplasms
IMAGE: Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) (in months) from start of PRRT for all patients with G3 NENs (A), and in subgroups with Ki-67 index of… view more Credit: J Zhang et al., THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Germany. Peptide receptor radionuclide therapy (PRRT) has…
Details